All Resources
Rapid Discovery of Therapeutic Antibodies for SARS-CoV-2

Learn how B Cell Antibody Discovery on the Beacon system can rapidly screen human B cell to discover antibodies against difficult targets such as viruses.

Your data is secure. We keep your personal information safe and do not share it with any third parties. By submitting this form, you agree to receive communications from Bruker Cellular Analysis and accept our Privacy Policy. You may unsubscribe at any time.

What's Inside

In this Poster we discuss:

Rapid identification of antigen-specific antibodies from B cells in less than 1 week.
Screening of frozen human PBMCs will enable identification of anti-viral antibodies from both acute and convalescent human patients exposed to SARS-CoV-2 and other viral pandemics.
Multiple assays for antibody specificity and cross-reactivity will enable down-selection of lead candidates.
The heavy/light chain genes encoding antigen-specific antibodies can be rapidly recovered using OptoSeq BCR.
Get the Poster